HEALTHCARE PROVIDER RESOURCES

XARELTO^® REPRINTS

REDUCING STROKE RISK IN NONVALVULAR ATRIAL FIBRILLATION (NVAF)

Patel MR et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

Post-marketing Safety Surveillance Study

Tamayo S et al. Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27,467 patients taking rivaroxaban

ROCKET AF Subgroup: Diabetes

Bensilal S et al. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)

ROCKET AF Subgroup: Moderate Renal Impairment

Fox KAA et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment

End-stage Renal Disease (ESRD)

Dias C et al. Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis

ROCKET AF Subgroup: Previous Stroke or Transient Ischaemic Attack

Hankey GJ et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF

ROCKET AF Subgroup: Heart Failure

van Diepen S et al. Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF

ROCKET AF Subgroup: Elderly

Halperin JL et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the ROCKET AF trial

DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) TREATMENT AND RISK REDUCTION

EINSTEIN DVT

The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism

EINSTEIN PE

The EINSTEIN PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism

Pooled EINSTEIN DVT and PE

Prins MH et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN–DVT and PE randomized studies

EINSTEIN CHOICE

EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism

XALIA

Ageno W et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study

EINSTEIN Cancer Subgroups

Prins MH et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE)

DEEP VEIN THROMBOSIS (DVT) PROPHYLAXIS AFTER KNEE OR HIP REPLACEMENT SURGERY

RECORD1

Eriksson BI et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty

RECORD2

Kakkar AK et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

RECORD3

Lassen MR et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty

XAMOS

Turpie AGG et al. A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment